Armata Pharmaceuticals, Inc. (ARMP)
5.795
+0.28
(+4.98%)
USD |
NYAM |
Sep 04, 13:54
Armata Pharmaceuticals Enterprise Value : 495.05M for Sept. 3, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 03, 2026 | 495.05M |
| September 02, 2026 | 495.42M |
| September 01, 2026 | 486.13M |
| August 31, 2026 | 494.67M |
| August 28, 2026 | 489.47M |
| August 27, 2026 | 491.70M |
| August 26, 2026 | 492.45M |
| August 25, 2026 | 496.53M |
| August 24, 2026 | 482.04M |
| August 21, 2026 | 479.44M |
| August 20, 2026 | 454.18M |
| August 19, 2026 | 478.33M |
| August 18, 2026 | 459.39M |
| August 17, 2026 | 456.41M |
| August 14, 2026 | 459.39M |
| August 13, 2026 | 469.04M |
| August 12, 2026 | 450.10M |
| August 11, 2026 | 447.87M |
| August 10, 2026 | 460.87M |
| August 07, 2026 | 464.96M |
| August 06, 2026 | 464.59M |
| August 05, 2026 | 464.59M |
| August 04, 2026 | 463.84M |
| August 03, 2026 | 477.59M |
| July 31, 2026 | 458.64M |
| Date | Value |
|---|---|
| July 30, 2026 | 467.56M |
| July 29, 2026 | 459.76M |
| July 28, 2026 | 465.70M |
| July 27, 2026 | 481.30M |
| July 24, 2026 | 463.10M |
| July 23, 2026 | 483.90M |
| July 22, 2026 | 484.64M |
| July 21, 2026 | 481.67M |
| July 20, 2026 | 477.96M |
| July 17, 2026 | 457.53M |
| July 16, 2026 | 429.67M |
| July 15, 2026 | 438.21M |
| July 14, 2026 | 435.61M |
| July 13, 2026 | 437.47M |
| July 10, 2026 | 448.24M |
| July 09, 2026 | 469.41M |
| July 08, 2026 | 479.44M |
| July 07, 2026 | 487.24M |
| July 06, 2026 | 492.07M |
| July 02, 2026 | 508.79M |
| July 01, 2026 | 508.42M |
| June 30, 2026 | 530.71M |
| June 29, 2026 | 604.27M |
| June 26, 2026 | 638.51M |
| June 25, 2026 | 605.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 615.81M |
| Amgen, Inc. | 283.41B |
| Anika Therapeutics, Inc. | 267.88M |
| BioCryst Pharmaceuticals, Inc. | 3.059B |
| Imunon, Inc. | 8.259M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 74.14M |
| Revenue (Quarterly) | 2.51M |
| Total Expenses (Quarterly) | -71.63M |
| EPS Diluted (Quarterly) | -0.272 |
| Gross Profit Margin (Quarterly) | 76.45% |
| Earnings Yield | -130.9% |
| Normalized Earnings Yield | -73.37 |